Biomm

Biomm EBITDA Margin

The EBITDA Margin of Biomm (BIOM3.SA) as of Nov 11, 2026 is 1.79 %. In the previous year, EBITDA Margin was -56.83 % — a change of -103.15% (higher).

EBITDA Margin

1.79 %

YoY

-103.15%

Last updated:

EBITDA Margin of Biomm is 2025 1.79 % . EBITDA Margin of Biomm was 2024 -56.83 % . It decreases by -103.15% higher compared to the previous year.

The Biomm EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-2,035.76 BRL
Jan 1, 2019
-527.85 BRL
Jan 1, 2020
-101.22 BRL
Jan 1, 2021
-61.06 BRL
Jan 1, 2022
-80.66 BRL
Jan 1, 2023
-61.28 BRL
Jan 1, 2024
-56.83 BRL
Jan 1, 2025
1.79 BRL
The Biomm EBITDA Margin history
YEAREBITDA MarginYoY
1.79 %-103.15%
-56.83 %-7.26%
-61.28 %-24.03%
-80.66 %+32.11%
-61.06 %-39.68%
-101.22 %-80.82%
-527.85 %-74.07%
-2,035.76 %-93.43%
-31,001.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

EBITDA Margin of Biomm is 1.79 % in 2025.

EBITDA Margin of Biomm changed from -56.83 % to 1.79 %, representing a -103.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Biomm since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Biomm with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Biomm

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Biomm